Notice
2025/10/07
OSAKA, Japan, Oct. 7, 2025 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; hereafter "Shionogi") announced that it extends its heartfelt congratulations to Dr. Shimon Sakaguchi, Distinguished Professor at Osaka University’s Immunology Frontier Research Center, on being awarded the Nobel Prize in Physiology or Medicine.
“Dr. Sakaguchi’s outstanding contributions to immunology—particularly his discovery of regulatory T cells (Tregs) and elucidation of their functions—have greatly advanced our understanding of autoimmune diseases and cancer immunotherapy. We express our deepest respect for his world-leading achievements and wish him continued success in his future endeavors," said Isao Teshirogi, Ph.D., Chief Executive Officer of Shionogi.
Since 2014, Shionogi has operated a collaborative research course within Osaka University’s Center of Medical Innovation and Translational Research (CoMIT), conducting cutting-edge research on tumor immunity and Tregs under Dr. Sakaguchi’s guidance. Through this collaboration, we identified CCR8 as a molecule specifically expressed on tumor-infiltrating regulatory T cells. Building on this discovery, we are actively advancing Phase 1b/2 clinical trials of S-531011, an anti-CCR8 antibody therapeutic, in oncology.
Dr. Sakaguchi’s Nobel Prize recognition reaffirms the importance of developing S-531011. Leveraging the knowledge gained through this collaboration and under his guidance, we will accelerate the development of S-531011 and strive to deliver this innovative treatment option to patients as quickly as possible.
Forward-Looking Statements
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
For Further Information, Contact:
SHIONOGI Website Inquiry Form: https://www.shionogi.com/global/en/contact.html